Viscoelastic Testing

A new article in Diagnostics by Smudla, Schöchl, Andreas Calatzis and colleagues asks an important question in viscoelastic testing: Is “physiological lysis” really plasmin-mediated fibrinolysis? Using the ClotPro system, with APIRO Diagnostics Kft. assays and consumables, the authors compared a tissue factor-activated EX-assay with an AP-assay containing tranexamic acid to inhibit fibrinolysis in 120 healthy adults. The key finding: low maximum lysis values were essentially

A recent single-centre randomised feasibility trial explored ClotPro-guided, low-dose, prolonged systemic thrombolysis for high- and intermediate-high-risk acute pulmonary embolism patients in the ICU. Instead of giving every patient the standard 100 mg rtPA over 2 hours, the viscoelastometry-guided group received an individualised infusion adjusted according to real-time coagulation and fibrinolysis results, alongside repeated echocardiography to monitor right ventricular re

A recent international survey on anticoagulation practices in ECMO highlights significant variability in monitoring strategies. While unfractionated heparin remains the standard, bivalirudin is now routinely used in over 50% of centers. Yet most institutions still rely heavily on aPTT — a test known to lack specificity in complex inflammatory and critical care states. More specific assays for direct thrombin inhibitors (e.g., DTT/DTI) remain unavailable or slow to provide r

Between analytical limitations in complex ECMO patients and delays in turnaround time, there is a growing need to rethink how we monitor anticoagulation and fibrinolysis at the bedside. 🇦🇺 Here in Australia, there is an exciting opportunity to advance this field through collaborative research using hashtag#Multiclot viscoelastic assays, including to better understand real-time coagulation dynamics and support more individualized anticoagulation strategies in ECMO. If you'

Exciting to see ongoing innovation in perioperative bleeding management and antifibrinolytic strategies. Australia offers outstanding opportunities to collaborate in cardiac surgery, haemostasis, and viscoelastic testing research. A recent prospective study compared two tranexamic acid (TXA) strategies in adult patients undergoing isolated CABG: • Triple-dose IV bolus • IV bolus followed by continuous infusion The triple-bolus regimen resulted in significantly lower postope

It has been a privilege and a pleasure to support nearly all of Andreas’s innovations over the past 15 years. The journey from the early days of innovation to today's MultiClot system is not only a testament to technological excellence but also to the persistence of a vision rooted in clinical relevance and collaboration. This new platform represents more than just technical progress—it reflects the collective wisdom of decades of development, multidisciplinary input, and fro

A recent proof-of-concept study published in Neurol. Int. 2025 has assessed the effectiveness of ClotPro® viscoelastic point-of-care testing in quickly evaluating DOAC activity among acute ischemic stroke patients to assist in intravenous thrombolysis (IVT) decisions. ClotPro® successfully identified 37.5% (15 patients) as having subtherapeutic levels, allowing 7 of them to undergo IVT. This highlights the potential of real-time whole blood hemostatic assessment at the point

A nice review of viscoelastic devices including the #ClotPro which has the advantage of having the largest panel of tests including...

Great to see our two products #Multiplate and #ClotPro in this recent study just published in Anesthesia journal to assess the...

In addition to established thromboelastometry assays, #ClotPro provides a unique assay that can evaluate the inhibitory effect on Xa...

The authors review major studies that have assessed fibrinogen treatment in trauma, cardiac surgery, end-stage liver disease, postpartum hem